Beacon Biosignals scores $27M to bring AI to EEG analysis
Electroencephalography (EEG) is a decades-old technique for collecting brain activity and analysing the results. Artificial intelligence is being used in these tests by Beacon Biosignals, and the neurotechnology startup has found a ready market in pharmaceutical companies looking to determine how well their experimental brain medicines are working. Beacon Biosignals now has a new source of funding: $27 million.
General Catalyst led the company’s recently announced Series A round of investment.Electrodes are attached to the patient’s scalp during an electroencephalogram (EEG) procedure. Those electrodes capture electrical signals from the brain over a period of time, usually up to an hour. Clinicians can figure out what’s going on in the brain by studying those signals. This knowledge can aid in the diagnosis of brain and sleep disorders. EEG analysis, on the other hand, is time consuming, and the interpretation of these tests varies from one doctor to the next. Beacon Biosignals claims that its technology can overcome the drawbacks of human EEG analysis.
Follow Startup Story
Related Posts
